Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, and has entered into a licensing deal with a subsidiary of Adapt Pharma Limited. Lightlake also has completed a Phase II clinical trial to treat Binge Eating Disorder.

  Learn more about our products in development.
Opioid Overdose Reversal
Binge Eating Disorder Treatment
Bulimia Nervosa Treatment
NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration

LLTP Receives Second Funding Commitment From a Prominent International Research and Development Foundation
LLTP Announces FDA Accepts for Review Adapt Pharma Limited's NARCAN(R) (Naloxone Hydrochloride) Nasal Spray
LLTP Announces Adapt Pharma Limited Submits NDA To FDA For Narcan® (naloxone) Nasal Spray
LLTP Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
LLTP Announces Fast Track Designation From FDA For Intranasal Naloxone Treatment To Reverse Opioid Overdose
LLTP Appoints Arvind Agrawal Executive
Vice President, Medical Affairs
(archived releases)